Role of estrogens in the secondary hormonal manipulation of hormone refractory prostate cancer

Journal of the Pakistan Medical Association

Volumn 54, Issue 9, 2004, Pages 445-447

  Siddiqui, K ^a   Abbas, F ^a   Biyabani, S R ^a   Ather, M H ^a   Talati, J ^a  

^a AGA KHAN UNIVERSITY   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; FOSFESTROL; HEPARIN; PROSTATE SPECIFIC ANTIGEN; WARFARIN;

ADULT; AGE; AGED; ARTICLE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER STAGING; CASTRATION; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; DEEP VEIN THROMBOSIS; ESTROGEN THERAPY; GYNECOMASTIA; HORMONAL THERAPY; HUMAN; MALE; METASTASIS; MORBIDITY; ORCHIECTOMY; PROSTATE CANCER; TREATMENT FAILURE;

ADENOCARCINOMA; ADMINISTRATION, ORAL; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; COHORT STUDIES; DIETHYLSTILBESTROL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PAKISTAN; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 6344229192     PISSN: 00309982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Jemal A, Murray T, Samuels A, et al. Cancer statistics 2003. CA Cancer 2003;53:5-26.
2. Malik IA, Khan WA, Khan ZK. Pattern of malignant tumors observed in a university hospital: a retrospective analysis. J Pak Med Assoc 1998;48:120-2.
3. Quinn M, Babb P. Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part I: international comparisons.: BJU Int 2002;90:162-73.
4. Srinivas V, Mehta H, Amin A, et al. Carcinoma of the prostate - state at initial presentation. Int Urol Nephrol 1995;27:419-22.
5. Huggin C, Hodges C. Studies on prostate cancer: 1. The effects of castration, of estrogen and of androgen injection on serum phosphatase, in metastatic carcinoma of the prostate. Cancer Res 1941;1:293-7.
6. Gittes R. Carcinoma of the prostate. N Eng J Med 1991;324:236-45.
7. Small EG, Vogalzang NJ. Second line hormone therapy for advance prostate cancer; shift in paradigm. J Clin Oncol, 1997;15:382-8.
8. Savrese DM, Halabi S, Hars V, et al. Phase II study of docetaxel, estramustine, and low dose cortisone in men with hormone refractory prostate cancer: a final report of CALBG. 9780 Cancer and Leukemia Group B. J Clin Oncol 2001;19:2509-16.
9. Tannok IF, Osoba D, Stockler MR, et al. Chemotherapy with Mitoxantrone plus prednisone or prednisone alone for symptomatic hormone resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996;14:1756-64.
10. Droz J P, De Smedt E, Kattan J, et al. Phase 1 trial of high-dose fosfestrol in hormone-refractory adenocarcinoma of the prostate. Prostate. 1994;24:62-6.
11. Kattan J, Droz JP, Culine S. High dose fosfestrol in phase I-II trial for the treatment of hormone-resistant prostatic adenocarcinoma. Bull Cancer 1993;80:248-54.
12. Droz JP, Kattan J, Bonnay M, et al. High-dose continuous-infusion fosfestrol in hormone-resistant prostate cancer. Cancer 1993;71(3 Suppl):1123-30.
13. Kelly WK, Scher HI, Mazumdar M, et al. Prostate specific antigen as a measure of disease outcome in hormone refractory prostatic cancer. J Clin Oncol 1993;11:607-15.